Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests. (see Section 4.4).
The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy.
The FDA) has approved Bio-T-Gel, which is licensed by BioSante to Teva Pharmaceuticals USA, Inc. Bio-T-Gel is a testosterone gel...
Galderma announced that it has received a Positive Opinion from 16 concerned European regulatory agencies for the market approval of...
The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched by ANI Pharmaceuticals as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the FDA.
Endo International plc has announced that it has introduced the first and only generic 2% topical testosterone gel, an authorized...
Allergan plc announced that the Company has received approval from the FDA to market Aczone (dapsone) Gel, 7.5%, a new...
KLOX Technologies has received CE mark approval in Europe for the topical photo-converter gel component in its LumiCleanse system, a...
Sol-Gel Technologies, Ltd. announced an update regarding the FDA approval process for Epsolay (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for Epsolay is April 26, 2021.
Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature.